Prior to ASCO, Breaking Data asked 30 oncologists to rate each abstract in terms of their level of interest. The chart depicts pre-ASCO oncologist interest in the data. Data regarding KEYTRUDA® in mCRPC and aNSCLC (Keynote 199, Keynote 042 and Keynote 407) generated the most interest. Oncologists were also interested in the OPDIVO® update for stage III/IV melanoma (CheckMate 238).
ABSTRACTS:
PROSTATE | KEYNOTE-199: Pembrolizumab for docetaxel-ref metastatic castration-resistant prostate cancer
LUNG | KEYNOTE-042: Pembro vs platinum-based chemo as 1L therapy for advanced NSCLC with a PD-L1 tumor proportion score ≥1%: Open-label, phase 3
LUNG | KEYNOTE-407: Phase 3: carbo plus paclitaxel or nab-paclitaxel ± pembrolizumab for patients with metastatic squamous NSCLC
MELANOMA | CheckMate 238: Adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase III trial
LUNG | IMpower131: Primary PFS and safety analysis of a randomized phase 3 study of atezolizumab + carbo + pac or nab-pac vs carbo + nab-pac in 1L advanced squamous NSCLC
BREAST | SANDPIPER: Phase 3 study of taselisib + fulvestrant vs fulvestrant in patients with ER-positive, PIK3CA-mutant, locally advanced or metastatic breast cancer
RET-altered Cancers | phase 1: LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers
BREAST | MONALEESA-3: Ribociclib + fulvestrant in postmenopausal women with HR+, HER2– advanced breast cancer
Source: Breaking Data: 2018 American Society of Oncology (ASCO) Impact Analysis Report: Solid Tumors
advanced non-small cell lung cancer (aNSCLC)
docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)
